PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis

被引:458
作者
Jiang, Bing-Hua [1 ,2 ,3 ]
Liu, Ling-Zhi [1 ,2 ]
机构
[1] W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA
[2] W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA
[3] Nanjing Med Univ, Dept Pathol, Ctr Canc, Nanjing 210029, Jiangsu, Peoples R China
来源
ADVANCES IN CANCER RESEARCH, VOL 102 | 2009年 / 102卷
关键词
ENDOTHELIAL-GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; PHASE-II TRIAL; NF-KAPPA-B; HYPOXIA-INDUCIBLE FACTOR; ADVANCED SOLID TUMORS; RENAL-CELL CARCINOMA; RECURRENT MALIGNANT GLIOMA; SMOOTH-MUSCLE-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET;
D O I
10.1016/S0065-230X(09)02002-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Phosphatidylinositol 3-kinase (PI3K) and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) signaling pathway play an important role in multiple cellular functions such as cell metabolism, proliferation, cell-cycle progression, and survival. PI3K is activated by growth factors and angiogenesis inducers such is vascular endothelial growth factor (VEGF) and angiopoietins. The amplification and Mutations of PI3K and the loss of the tumor suppressor PTEN are common in various kinds of human solid tumors. The genetic alterations of upstream and downstream of PI3K signaling molecules such as receptor tyrosine kinases and AKT, respectively, are also frequently altered in human cancer. PI3K signaling regulates tumor growth and angiogenesis by activating AKT and other targets, and by inducing HIF-1 and VEGF expression. Angiogenesis is required for tumor growth and metastasis. In this review, we highlight the recent studies on the roles and mechanisms of PI3K and PTEN in regulating tumorigenesis and angiogenesis, and the roles of the downstream targets of PI3K for transmitting the signals. We also discuss the crosstalk of these signaling molecules and Cellular events during tumor growth, metastasis, and tumor angiogenesis. Finally, we Summarize the potential applications of PI3K, AKT, and mTOR inhibitors and their Outcome in clinical trials for cancer treatment. (C) 2009 Elsevier Inc.
引用
收藏
页码:19 / 65
页数:47
相关论文
共 278 条
[51]   Akt2 regulates cardiac metabolism and cardiomyocyte survival [J].
DeBosch, Brian ;
Sambandam, Nandakumar ;
Weinheimer, Carla ;
Courtois, Michael ;
Muslin, Anthony J. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (43) :32841-32851
[52]   Pten is essential for embryonic development and tumour suppression [J].
Di Cristofano, A ;
Pesce, B ;
Cordon-Cardo, C ;
Pandolfi, PP .
NATURE GENETICS, 1998, 19 (04) :348-355
[53]   Glycogen synthase kinase 3β regulates cyclin D1 proteolysis and subcellular localization [J].
Diehl, JA ;
Cheng, MG ;
Roussel, MF ;
Sherr, CJ .
GENES & DEVELOPMENT, 1998, 12 (22) :3499-3511
[54]   Using structure to define the function of phosphoinositide 3-kinase family members [J].
Domin, J ;
Waterfield, MD .
FEBS LETTERS, 1997, 410 (01) :91-95
[55]   Mechanisms and consequences of activation of protein kinase B/Akt [J].
Downward, J .
CURRENT OPINION IN CELL BIOLOGY, 1998, 10 (02) :262-267
[56]   A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas [J].
Duran, I. ;
Kortmansky, J. ;
Singh, D. ;
Hirte, H. ;
Kocha, W. ;
Goss, G. ;
Le, L. ;
Oza, A. ;
Nicklee, T. ;
Ho, J. ;
Birle, D. ;
Pond, G. R. ;
Arboine, D. ;
Dancey, J. ;
Aviel-Ronen, S. ;
Tsao, M-S ;
Hedley, D. ;
Siu, L. L. .
BRITISH JOURNAL OF CANCER, 2006, 95 (09) :1148-1154
[57]   mTOR and cancer therapy [J].
Easton, J. B. ;
Houghton, P. J. .
ONCOGENE, 2006, 25 (48) :6436-6446
[58]   The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism [J].
Engelman, Jeffrey A. ;
Luo, Ji ;
Cantley, Lewis C. .
NATURE REVIEWS GENETICS, 2006, 7 (08) :606-619
[59]   Current development of mTOR inhibitors as anticancer agents [J].
Faivre, Sandrine ;
Kroemer, Guido ;
Raymond, Eric .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (08) :671-688
[60]   Role of class II phosphoinositide 3-kinase in cell signalling [J].
Falasca, M. ;
Maffucci, T. .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2007, 35 :211-214